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Immunomodulatory drugs (IMiDs) are effective therapeutics for multiple myeloma (MM),
where in different clinical settings they exert their function both directly on MM cells
and indirectly by modulating immune cell subsets, although with not completely
defined mechanisms. Here we studied the role of IMiDs in the context of autologous
hematopoietic stem cell transplantation on the T cell subset distribution in the bone
marrow of newly diagnosed MM patients. We found that after transplantation pro-tumor
Th17-Th1 and Th22 cells and their related cytokines were lower in patients treated with
IMiDs during induction chemotherapy compared to untreated patients. Of note, lower
levels of IL-17, IL-22, and related IL-6, TNF-α, IL-1β, and IL-23 in the bone marrow
sera correlated with treatment with IMiDs and favorable clinical outcome. Collectively,
our results suggest a novel anti-inflammatory role for IMiDs in MM.
Keywords: multiple myeloma, immunomodulatory drugs, autologous hematopoietic stem cell transplantation,
bone marrow, anti-tumor and pro-tumor T cell subsets
INTRODUCTION
Multiple Myeloma (MM) is a plasma cell neoplastic disorder primarily localized in the
bone marrow (BM), where interactions between neoplastic cells and cells within the tumor
microenvironment (i.e., mesenchymal stromal cells, endothelial cells, osteoblasts, osteoclasts, and
immune cells) mediate disease development and progression (1–3).
Th cells play fundamental regulatory function in adaptive immune responses and in antitumor
immunity being, according to their secretory cytokine profile, either anti-tumor or pro-tumor (4).
In MM imbalanced Th cell polarization and subset distribution in the BM niche largely impact on
disease progression (5).
Immunomodulatory drugs (IMiDs), namely thalidomide and its derivatives lenalidomide and
pomalidomide, are major therapeutics in the treatment of MM (6), where their efficacy has been
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demonstrated in newly diagnosed patients either eligible or
ineligible for autologous hematopoietic stem cell transplantation
(ASCT), in the maintenance setting after ASCT and in
refractory/relapsed disease (6).
In MM, in addition to anti-proliferative and pro-apoptotic
effects on malignant cells, IMiDs exert immune regulatory
function and interfere with tumor microenvironment
interactions (7). In vitro IMiDs enhanced T cell proliferation,
IL-2 and IFN-γ secretion and NK cell activation (8, 9),
lenalidomide improved immune checkpoint blockade-induced
immune responses (10) and inhibited T regulatory cell (Treg)
proliferation and suppressor function (11). In vivo lenalidomide
augmented (i) vaccine responses and endogenous anti-tumor
immunity (12), (ii) the number of central and effector memory
CD8+ T cells, Tregs and CD14+CD15+ myeloid derived
suppressor cells in patients that received lenalidomide as
monotherapy or in combination with other treatments (13), (iii)
the number of Tregs in patients in consolidation/maintenance
therapy (14, 15), (iv) anti-myeloma specific T cell responses in
patients that received lenalidomide as consolidation therapy after
ASCT (16), and (v) the number of IFN-γ and IL-21 producing
cells in the setting of maintenance therapy (17). Treatment
with lenalidomide was also associated with impaired long-
term thymic reconstitution and decreased number of CD4+
and CD8+ effector terminally differentiated T cells (14, 15)
and reduced PD-1 expression on T cells in the maintenance
setting (18).
A prospective randomized trial comparing induction
regimens prior to ASCT including or not thalidomide (i.e.,
bortezomib-thalidomide-dexamethasone) vs. bortezomib-
cyclophosphamide-dexamethasone) recently reported
significantly higher overall clinical response rate in the
bortezomib-thalidomide-dexamethasone arm (19).
In this study, we evaluated in newly diagnosed MM patients
the impact of IMiDs used in the induction chemotherapy
preceding ASCT on the distribution of T cell subsets and related
cytokines in the BM after transplantation and whether changes




Forty-four newly diagnosed MM patients, who had been
hospitalized at the Hematology Department of our Institution
and received ASCT as first line therapy, were selected for
the study. The Institutional Ethics Committee (Comitato Etico
Fondazione Centro San Raffaele, Istituto Scientifico Ospedale
San Raffaele) had approved the study protocol and written
informed consent was obtained from all donors. Clinical data
and information on the induction chemotherapy received by
each patient are reported in Table 1. BM mononuclear cells were
isolated by density gradient centrifugation with Ficoll-PaqueTM
Abbreviations: ASCT, autologous stem cell transplantation; BM, bone marrow;
IMiDs, immunomodulatory drugs; MM, multiple myeloma; Treg, T regulatory
cells.
Plus (GE Healthcare, Uppsala, Sweden), frozen in fetal bovine
serum (Lonza, Milan, Italy) + 10% DMSO (Sigma-Aldrich,
Milan, Italy), and stored according to standardized operating
procedures by the Institutional Biobank. BM mononuclear cells
were used after thawing and viable cell counting. BM sera
were taken and collected according to standardized operating
procedures by the Institutional Biobank. Briefly, non-heparinized
BM blood (5–7ml) was incubated for 1 h at room temperature
to achieve complete clotting. Then samples were centrifuged
at 1,600 g without brake for 10min at 4◦C and supernatants
transferred in cryovials and stored in liquid nitrogen until use.
Flow Cytometry Analysis
The following antibodies were used: Pacific blue-conjugated CD3
(clone UCHT1) from Dako Cytomation (Cernusco sul Naviglio
(MI), Italy); PerCP-conjugated CD4 (clone L200), PE-conjugated
CD25 (clone 2A3), PE-conjugated IL-13 (clone JES10-5A2), and
APC-conjugated IL-5 (clone TRFK5), all from BD Biosciences
(Milan, Italy); PE-Cy7-conjugated CD127 (clone R34.34) from
Beckman Coulter (Cassina De’ Pecchi (MI), Italy); PE-Cy7-
coniugated IL-22 (clone 22URTI) from eBioscience (Milan,
Italy); FITC-conjugated CD3 (clone UCHT1), FITC-conjugated
IFN-γ (clone B27), Alexa Fluor488-conjugated IL-4 (clone MPA-
25D2), Alexa Fluor647-conjugated IL-17 (clone BL168), all from
Biolegend (Milan, Italy). For the study of the percentage of T cells
secreting distinct effector cytokines, thawed BM mononuclear
cells were rested at room temperature for 30min before viable cell
counting and then cultured at a cell density of 2× 106 cells/ml for
5 h in x-vivo-15 medium (Lonza), supplemented with penicillin
(100 U/ml), streptomycin (100 U/ml), and 3% human serum
type AB (Lonza), in the absence or the presence of 50 ng/ml
PMA (phorbol-12-myristate-13-acetate) and 1µg/ml ionomycin
(both from Sigma-Aldrich) to induce cytokine production. After
2 h, 10µg/ml brefeldin A (Sigma-Aldrich) was added to both
unstimulated and stimulated cells. After stimulation, cells were
harvested, washed and stained first for the surface markers
CD3 and CD4 and then for intracellular cytokines, using a kit
from BD Biosciences, following the manufacturer’s instructions.
In detail, for intracellular cytokine staining cells were fixed,
permeabilized with Cytofix/Cytoperm buffer, and incubated
with antibodies diluted in Perm/Wash buffer. Percentages
of cells positive for intracellular cytokine expression were
referred to total CD3+ T cells because a clear-cut distinction
between CD4+ and CD4− T cells was hampered by the
downregulation of surface CD4 expression on T cells stimulated
with PMA + ionomycin (Figure S1). For Treg staining, cells
were first stained for the surface antigens CD3, CD4, CD25,
and CD127 and then fixed, permeabilized, and stained for
the nuclear transcription factor FoxP3 with the dedicated
FoxP3/Transcription Factor Staining Buffer from eBioscience,
according to the manufacturer’s instructions. Percentages of Treg
cells, identified as CD3+CD4+CD127−CD25+FoxP3+ cells,
were also referred to total CD3+ T cells. Cells were analyzed
using a FACSCanto flow cytometer (BD Biosciences) and data
were illustrated by FlowJo software (Tree Star Inc., Ashland, OR,
USA).
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Cytokine Measurements
Cytokines in BM sera were measured using ELISA kits from
Mabtech (Milan, Italy) (i.e., IL-1β, TNF-α, IFN-γ, IL-4, IL-5, IL-
6, IL-13, IL-17, IL-22, and IL-23), following the manufacturer’s
instructions.
Statistical Analysis
Statistical significance was determined with Mann Whitney U
test and Wilcoxon Signed-Rank Test, as reported in the figure
legends. In addition, to evaluate the equality of variances for
the values in the IMiD-treated vs. the IMiD-untreated group
FIGURE 1 | Gating strategy for immunophenotypic analyses in representative samples of BM mononuclear cells. (A) Panels represent, from left to right: the pulse
geometry R1 gate (in FSC-A x FSC-H dot plot of all the analyzed cells) used to exclude doublets, the morphology-based R2 gate of leukocytes (in FSC-A x SSC-A dot
plot of R1-gated cells) and the R3 gate of T cells (i.e., CD3+ cells of R2-gated leukocytes). (B) Left panel: quadrant gates defining the expression and the percentage
of IL-17 and IFN-γ in R3-gated CD3+ T cells; right panel: quadrant gates defining the expression of IL-17 and IL-22 in R3-gated CD3+ T cells. (C) Panels represent,
from left to right, the quadrant gates defining expression and the percentage of IFN-γ+, IL-13+, IL-4+, IL-5+, and TNF-α+ cells in R3-gated CD3+ T cells. (D) Dot
plots showing the gates used to identify and enumerate the percentage of Treg cells (CD4+CD127−CD25+FoxP3+) in R3-gated CD3+ T cells. From left to right: R4
gate represents the percentage of CD4+ cells among total CD3+ T cells (i.e., R3-gated cells); R5 gate represents the percentage of CD127− cells among total CD4+
T cells (i.e., R4-gated cells); the upper right quadrant gate in the CD25 x FoxP3 dot plot identifies bona fide Treg cells (i.e., CD25+FoxP3+ T cells in R5-gated
CD4+CD127− T cells). Numbers within the plots represent percentages of R gates (A,D) and quadrant statistics (B–D).
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of patients we performed the Levene’s test with no statistical
evidence to support difference between the variance of the
distributions. Statistical analyses were performed with an alpha
level of 5% using GraphPad Prism version 5.0 forMac (GraphPad
Software), thus values of p < 0.05 were considered significant.
RESULTS
We studied forty-four newly diagnosed MM patients, who had
received ASCT as frontline therapy and whose clinical features
are detailed in Table 1. Patients were administered an induction
chemotherapy, most often consisting of a bortezomib-based
poly-chemotherapy (including or not thalidomide or, less
often, lenalidomide) followed by stem cell mobilization with
cyclophosphamide and G-CSF, high-dose melphalan and a single
or tandem ASCT (see Table 1 for dosage and schedule details).
BM mononuclear cells were analyzed by flow cytometry for
intracellular cytokine staining of the T cell subset-distinctive
cytokine patterns or directly for Treg specific markers within the
T cell fraction (see Figure 1 for gating strategy).
Firstly, we measured the frequency of distinct effector
cytokine-secreting T and Treg cell subsets in paired samples
at diagnosis and 3 months after ASCT (i.e., a time point
at which immune cells are mostly reconstituted), to evaluate
potential changes of the T cell subset distribution occurring early
after transplantation as a consequence of the complete therapy
received by the patients (i.e., induction regimen including or
not IMiDs, stem cell mobilization, chemotherapy and ASCT).
We found that T cells secreting Th1 (i.e., IFN-γ and TNF-α)
and Th2 (i.e., IL-13, IL-4, and IL-5) cytokines were significantly
increased after ASCT compared to those at diagnosis as well as
T cells coproducing IL-17 and IFN-γ, whereas T cells secreting
IL-17, IL-22, and Tregs (CD4+CD127−CD25+FoxP3+) were
not (Figure 2). Secondly, to evaluate the impact of IMiDs used
in the induction regimen, we focused on the frequency of the
T cell subsets in the post-ASCT time point and performed
analyses in patients grouped based on the absence or the
presence of IMiDs in the induction chemotherapy. We found
that IL-17+IFN-γ+ (i.e., mostly Th17-Th1, see Figure S1) and
IL-22+IL-17− (i.e., mostly Th22, see Figure S1) T cells were
significantly lower in the IMiD-treated compared to untreated
patients (Figure 3A). Remarkably, increased frequency of Th17-
Th1 and Th22 cell subsets correlated with development of
symptomatic MM and worse prognosis (25, 26), respectively.
FIGURE 2 | Frequency of distinctive cytokine secreting T cells and Tregs in newly diagnosed MM patients measured in paired BM samples at diagnosis and at 3
months after ASCT. The frequency of CD3+ T cells secreting IFN-γ, IL-13, IL-17, IL-22 (n = 25), IL-4, and IL-5 (n = 19), TNF-α (n = 18) and CD3+ T cells expressing
a Treg phenotype (i.e., CD4+CD127−CD25+FoxP3+) (n = 14) are reported. Responses significantly different by Wilcoxon Signed-Rank Test are indicated as:
*p < 0.05, **0.001 < p < 0.01 and ***p < 0.001.
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FIGURE 3 | Effects of IMiD treatment on ex-vivo distribution of T cell subsets and related cytokines in the BM of MM patients at 3 months after ASCT. (A) Percentages
of CD3+ T cells secreting the indicated cytokines and CD3+ T cells expressing a Treg phenotype (i.e., CD4+CD127−CD25+FoxP3+), as assessed by surface and
intracellular staining analyses, in the BM of patients grouped based on the absence (–IMiDs, n = 10 for T cells and n = 6 for Tregs) or the presence (+IMiDs, n = 34
for T cells and n = 23 for Tregs) of IMiDs in the induction chemotherapy. Data from each patient are represented as black-filled triangles. (B,C) BM serum levels of the
indicated cytokines in MM patients grouped as above (-IMiDs, n = 7; +IMiDs, n = 31). Data from each patient are represented as gray-filled circles. Responses
significantly different by Mann-Whitney test are indicated as: *p < 0.05, **0.001 < p < 0.01 and *** p < 0.001.
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Indeed, poly-functional Th17-Th1 were found increased in
the BM of MM patients compared to those of patients with
pre-neoplastic gammopathy (25), and we previously reported
increased frequency of Th22 cells in the blood and BM of
patients with stage III disease at diagnosis and refractory/relapsed
disease compared to those of asymptomatic patients or patients
with stage I/II disease (26). Total IL-17+ and IL-22+ T cells
were also lower within BM T cells from IMiD-treated compared
to untreated patients (Figure 3A). In agreement with previous
reports (9, 13), IFN-γ+ secreting cells were higher in the IMiD-
treated compared to the untreated group (Figure 3A), whereas
T cells secreting the other cytokines (i.e., IL-13, IL-4, IL-5, and
FIGURE 4 | Correlation between cytokine levels in the BM at 3 months after ASCT, clinical outcome and induction chemotherapy regimens. (A) MM patients (n = 37)
were grouped based on the clinical status: REF, refractory disease (n = 2); PR: partial response (n = 6); VGPR, very good partial response (n = 14); CR, complete
response (n = 15). (B) MM patients with VGPR (n = 13) were grouped based on the absence (–IMiDs) (n = 4) or the presence (+IMiDs) (n = 9) of IMiDs in the
induction chemotherapy. Responses significantly different by Mann-Whitney test are indicated as: *p < 0.05 and **0.001 < p < 0.01.
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TNF-α) and Tregs were comparable between the two groups
(Figure 3A).
We then measured the levels of the same cytokines in the BM
sera. We found that, as a result of the complete therapy received
by the patients, in paired samples at diagnosis and at 3 months
after ASCT IFN-γ, IL-13, IL-4, IL-5, TNF-α, IL-17, and IL-22
were all significantly increased at 3 months after transplantation
(Figure S2A). In agreement with the T cell data, when we
considered the levels of the cytokines in the BM sera after ASCT
in patients grouped based on the absence or the presence of
IMiDs in the induction chemotherapy, we found that the levels
of IL-17 and IL-22 were significantly lower in the BM sera of
IMiD-treated vs. untreated patients, and those of Th2 cytokines
(i.e., IL-13, IL-4 and IL-5) were not (Figure 3B). On the contrary,
the levels of IFN-γ and TNF-α were both significantly lower
in IMiD-treated patients (Figure 3B), suggesting that the total
amount of these cytokines in the BM sera after transplantation
possibly depends on immune cells, other than T cells, which may
be differentially targeted by the drugs used in the two induction
chemotherapy regimens.
Next, we measured the BM serum levels of cytokines
implicated in Th17-Th1 and Th22 cell polarization/expansion,
namely, in addition to TNF-α, IL-6, IL-1β, and IL-23 (27). We
did not find any significant change in the level of these cytokines
when comparing paired BM sera at diagnosis and at 3 months
after ASCT (Figure S2B). Interestingly, these cytokines were all
significantly reduced in IMiD-treated vs. untreated patients in the
BM sera after ASCT (Figure 3C).
Together, these data show that IMiD-including therapies are
associated with a lower frequency in the BM at 3 months after
transplantation of pro-tumor Th17-Th1 and Th22 cells and of
the serum levels of their distinctive cytokines and cytokines
implicated in their polarization/expansion.
Lastly, to assess potential correlations between the
immunological changes observed, the clinical status and
the use of IMiDs in the induction chemotherapy, we analyzed
the levels of cytokines in patients grouped according to their
clinical status at 3 months after ASCT (Table 1). We found that
IL-17, IL-22, TNF-α, IL-6, IL-23, and IL-1β were all significantly
lower in patients with complete response compared to patients
with refractory disease or partial response, whereas IFN-γ did
not significantly change (Figure 4A). IL-6, IL-23, and IL-1β
were also significantly lower in patients with complete response
compared to those with very good partial response (Figure 4A).
As the cohort of patients that received IMiDs had better
clinical outcome (complete response in 44 vs. 10% patients,
respectively, see Table 1), to exclude that the immunological
changes observed were simply the consequence of reduced
tumor burden and not associated to IMiD-driven immune
modulation, we compared the cytokine profile in IMiD-
treated vs. untreated patients within patients with very good
partial response (i.e., patients who had achieved very deep
responses to therapy, yet still have some residual markers
of disease). Although the number of patients compared is
relatively small, we found that IL-17, IL-22, IL-6, and IL-1β
were significantly lower in IMiD-treated compared to untreated
patients (Figure 4B).
Together, these data suggest that the better clinical responses
observed in IMiD-treated patients depend not only on the well-
known anti-proliferative effects of IMiDs on myeloma cells (6)
but possibly also on immune regulatory functions, among which
the down-modulation of pro-tumor Th17-Th1, Th22 cells and
their related cytokines.
CONCLUSIONS
In this study we report that (i) pro-tumor Th17-Th1 and Th22
cells and their related cytokines in the BM after transplantation
are lower in patients treated with IMiDs during induction
chemotherapy compared to untreated patients and (ii) the levels
of the same cytokines are lower in patients with favorable clinical
outcome (i.e., complete response) compared to patients with
persistent disease (i.e., refractory disease and partial response).
In agreement with previous reports (9, 13) we found higher
numbers of IFN-γ secreting T cells in the BM of patients
treated with IMiDs in the induction chemotherapy: however,
even though the levels of IFN-γ in the BM sera were increased
after transplantation compared with those at diagnosis, we did
not find a significant correlation between the levels of IFN-γ and
the clinical outcome after transplantation.
Conflicting results are reported concerning the role of IMiDs
on Tregs: while in vitro lenalidomide reduced the number of
Tregs (11), in vivo studies showed an increase in the number
of Tregs in different clinical settings (13–15). In our study we
did not find significant changes in the numbers of Tregs neither
between diagnosis and after transplantation nor between IMiD-
treated and untreated patients. Factors such as the clinical setting
in different studies (i.e., consolidation and/or maintenance vs.
induction chemotherapy) and the site of investigation (i.e.,
peripheral vs. BM blood) may account for these differences.
Our findings are particularly relevant because of the pro-
tumor role of IL-17 and IL-22 in MM. IL-17 promotes MM
cell growth/survival by interaction with the IL-17 receptor
expressed on MM cells, and inhibits immune cell functions
(28). In addition, expansion of Th17 cells correlates with
development of bone lesions (29, 30), possibly through IL-
17-induced upregulation in BM cells of RANKL, which is a
differentiation factor for osteoclasts [rev. in (31)]. A reduction
in the RANKL/osteoprotegerin ratio and bone osteolysis was
reported in MM patients with relapsed/refractory disease treated
with thalidomide-containing regimen (32, 33). In agreement
with this report, we found that the percentage of nuclear
magnetic resonance and/or positron emission tomography
negative patients as from evaluation after transplantation was
superior within the IMiD-treated compared to the untreated
group (data not shown). Whether the effect on bone disease
following treatment with IMiDs might at least partially depend
on IL-17 modulation through the RANKL signaling as well
as other mechanisms of bone remodeling [i.e., Wnt (34)
and LIGHT/TNFSF14 (35) signaling pathways] might warrant
further ad hoc investigation. Concerning IL-22, we previously
reported that this cytokine directly increases MM cell growth and
resistance to drug-induced cell death by binding to its IL22RA1
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receptor, which is aberrantly expressed on a fraction of primary
MM cells (26).
The immune regulation exerted by IMiDs has actually two
sides: they co-stimulate activation of immune responses, as in
hematologic cancers (6), but they can also dampen inflammatory
reactions, as in autoimmune and inflammatory disorders (36).
Such dual role conceivably depends on different immune cell
types targeted, such as T and NK cells and antigen presenting
cells, respectively (36). It is tempting to speculate that the use
of IMiDs during induction chemotherapy might have favored
the development and persistence of an anti-inflammatory BM
milieu responsible for the reduced frequency of Th17-Th1 and
Th22 cells, possibly through modulation of BM resident cells
(i.e., mesenchymal stromal cells) and/or immune cells persisting
in the BM or transferred within the autologous progenitor cell
reinfusion.
In summary, our results contribute to the characterization
of the immunomodulatory effects exerted by IMiDs in MM
and should be taken into consideration for the implementation
of new therapeutic strategies targeting IL-17 and IL-22 to be
combined with drugs already used in MM treatment, especially
in refractory/relapsed disease stages.
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